IL-12- or IFN-γ-depleted animals were BCG-resistant with a poor cancer-specific survival [16], whereas therapeutic strategies administering BCG along with Th1 cytokines and concurrent blocking of Th2 cells may enhance BCG-induced IFN-γ production and BCG vaccine efficacy [17–20]. The gene discussed is IFNG; the disease is cancer.